Plain-English translation of NCT06323447 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new device called PointCheck that uses hand imaging to detect severe neutropenia — a dangerous drop in infection-fighting white blood cells — in people being treated for lymphoma or myeloma. The device is non-invasive, meaning it doesn't require blood draws or needles. Researchers want to validate that this new tool is safe, easy to use, and accurate at catching this serious side effect early.
Many cancer treatments can lower white blood cell counts, which puts patients at serious risk for infections. Currently, doctors rely on frequent blood tests to monitor for this problem. This trial exists to see whether the new device can detect low white blood cells without needles, making monitoring faster, easier, and less burdensome for patients.
You likely qualify if…
You likely don't qualify if…
During this trial, you would undergo hand imaging scans using the PointCheck device at specified visits during your cancer treatment. The device takes images of your hands — specifically the nail beds — to assess blood flow patterns that may indicate low white blood cell counts. You would continue your regular cancer treatment and medical care as planned, and the study team would compare the device's readings with your standard blood tests to see how accurate it is.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
United States